文献速递肾小球疾病

尿血管紧张素原:抗中性粒细胞胞浆抗体相关肾小球肾炎活动性的指标

Urinary angiotensinogen: an indicator of active antineutrophil cytoplasmic antibody-associated glomerulonephritis.
PubMed 文献 · Nephrol Dial Transplant · 2019-01-01

这项前瞻性两阶段队列研究在ANCA-GN患者中评估尿血管紧张素原(UAGT)作为肾脏疾病活动性生物标志物的价值。第二阶段对50例患者随访24个月,显示UAGT在免疫治疗后下降、肾脏复发时升高。

要点

  • UAGT与ANCA-GN的细胞性新月体形成和活动性间质炎症相关。
  • UAGT预测新月体性ANCA-GN的AUC为0.88,优于白蛋白尿和eGFR。
  • UAGT在免疫治疗后下降、肾脏复发时升高,可用于监测疾病活动。

核心结论

  • UAGT可能用于评估ANCA-GN的疾病活动性和肾脏复发。

研究设计与样本

  • 前瞻性两阶段队列研究,第一阶段在69例测试集和25例验证集患者肾活检时检测UAGT。
  • 第二阶段在测试集50例患者中监测UAGT 24个月。

主要发现

  • UAGT在ANCA-GN患者中显著升高,与细胞性新月体形成和活动性间质炎症相关性良好。
  • 新月体性ANCA-GN患者的UAGT最高,UAGT最高四分位相比最低四分位与新月体性ANCA-GN风险增加6倍相关。
  • UAGT预测新月体性ANCA-GN的AUC为0.88,优于白蛋白尿(AUC=0.73)和eGFR(AUC=0.69),并改善临床标志物的诊断性能(P<0.034)。
  • 第二阶段随访中,UAGT在免疫治疗后下降,肾脏复发时升高。

关键数值与推荐

  • UAGT预测新月体性ANCA-GN的AUC=0.88,白蛋白尿AUC=0.73,eGFR AUC=0.69。
  • UAGT最高四分位相比最低四分位与新月体性ANCA-GN风险增加6倍相关。
  • UAGT改善临床标志物诊断新月体性ANCA-GN的性能(P<0.034)。

临床怎么用

  • UAGT或可作为ANCA-GN疾病活动性和肾脏复发的监测指标。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: One of the major challenges in improving the management of antineutrophil cytoplasmic antibody-associated glomerulonephritis (ANCA-GN) is the lack of a disease-specific indicator for histological lesions and disease activity. Here we tested the utility of urinary angiotensinogen (UAGT) as a biomarker of renal disease activity in ANCA-GN. METHODS: A prospective, two-stage cohort study was performed in ANCA-GN patients. In Stage I, UAGT was measured at the time of renal biopsy in 69 patients from two centers (test set) and 25 patients from two other centers (validation set). In Stage II, UAGT was monitored in 50 subjects in the test set for 24 months. RESULTS: In Stage I, UAGT significantly increased in ANCA-GN patients, correlating well with cellular crescents formation and active interstitial inflammation. Patients with crescentic ANCA-GN exhibited the highest UAGT compared with other histopathological classes of ANCA-GN. After multivariable adjustment, the highest quartile of UAGT, compared with the lowest quartile, associated with a 6-fold increased risk of crescentic ANCA-GN. For predicting crescentic ANCA-GN, UAGT [area under the receiver operating characteristics curve (AUC) = 0.88] outperformed albuminuria (AUC = 0.73) and estimated glomerular filtration rate (AUC = 0.69). UAGT improved the performance of those clinical markers in diagnosing crescentic ANCA-GN (P < 0.034), suggesting a role of UAGT in identifying active crescentic ANCA-GN. In Stage II, UAGT decreased after immunotherapy and increased at the time of renal relapse during the 2-year follow-up, suggesting the usefulness of UAGT to monitor disease activity over time. CONCLUSIONS: These results suggest the potential use of UAGT for assessing disease activity and renal relapse in ANCA-GN.

来源:Nephrol Dial Transplant,查看原文。版权归原作者所有。

引用

  1. Wu L, Yang M, Feng X, et al. Urinary angiotensinogen: an indicator of active antineutrophil cytoplasmic antibody-associated glomerulonephritis. Nephrol Dial Transplant. 2019. PMID: 29733413. doi:10.1093/ndt/gfy112

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。